Eventide Gilead
630-a Fitzwatertown Road 2nd Floor
Map
Phone: 877-453-7877
| Category: | Mid-Cap Blend | | Fund Family: | America First Funds | | Net Assets: | 690.00K | | Year-to-Date Return: | N/A | | Yield: | % | | Morningstar Rating: | N/A | | Fund Inception Date: | 01-Jul-08 |
|
Finny Kuruvilla
Lead Manager since
01-Jul-08 | | | Kuruvilla has been serving in various positions including as a resident physician at Brigham and Womens Hospital in Boston from July 2003 to the present. He also works as a research fellow at the Broad Institute of Harvard and MIT. Kuruvilla taught at Harvard University from September 2002 until June 2003. He is active in several Christian organizations, including a church in Cambridge, MA, in which he serves as a co-pastor. |
| Min Initial Investment: | $1,000 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $100 | | Min Subsequent Investment: | $50 | | Min Subsequent Investment, IRA: | $50 | | Min Subsequent Investment, AIP: | $100 |
|
| |
| The investment seeks to provide long-term capital appreciation. The fund invests primarily in a broad range of equity securities without limitation to market capitalization. It also seeks to avoid investing in securities of companies that are inconsistent with the ethical values of the Christian faith. The fund may invest in securities in companies domiciled outside the United States either directly or through American Depositary Receipts. |
| Last Dividend
| N/A | | Last Cap Gain
| N/A | | Annual Holdings Turnover
| N/A | | Average for Category:
| 91.13% |
|
| Expense | ETGLX | Category
Avg | | Total Expense Ratio: | %
| 1.35% | | Max 12b1 Fee: | 0.20%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.27% | | Max Deferred Sales Load: | 0.00%
| 2.52% | | 3 Yr Expense Projection*: |
$536 | $654 | | 5 Yr Expense Projection*: |
$N/A | $1,012 | | 10 Yr Expense Projection*: |
$N/A | $1,941 |
|
|
1.83% Nasdaq 0.00%
0.13 (1.72%) 
Profile
